Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients

James P. Stewart; Alan T. McGown; Joseph Prendiville; George Pettit; Brian W. Fox; John R. Arrand

doi:10.1007/BF00686030

Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients

James P. Stewart, Alan T. McGown, Joseph Prendiville, George Pettit, Brian W. Fox, John R. Arrand

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

Original language	English (US)
Pages (from-to)	89-91
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	33
Issue number	1
DOIs	https://doi.org/10.1007/BF00686030
State	Published - Jan 1 1993

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/BF00686030

Cite this

@article{5b8ed13685144d38a9cfece0ff88610b,

title = "Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients",

abstract = "Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.",

author = "Stewart, {James P.} and McGown, {Alan T.} and Joseph Prendiville and George Pettit and Fox, {Brian W.} and Arrand, {John R.}",

year = "1993",

month = jan,

day = "1",

doi = "10.1007/BF00686030",

language = "English (US)",

volume = "33",

pages = "89--91",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells

T2 - implications for use in immunocompromised patients

AU - Stewart, James P.

AU - McGown, Alan T.

AU - Prendiville, Joseph

AU - Pettit, George

AU - Fox, Brian W.

AU - Arrand, John R.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

AB - Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.

UR - http://www.scopus.com/inward/record.url?scp=0027482707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027482707&partnerID=8YFLogxK

U2 - 10.1007/BF00686030

DO - 10.1007/BF00686030

M3 - Article

C2 - 8269596

AN - SCOPUS:0027482707

SN - 0344-5704

VL - 33

SP - 89

EP - 91

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this